Eli Lilly's incretin manufacturing facility at Research Triangle Park in North Carolina
July 23, 2024 10:15 AM EDTUpdated July 25, 04:16 PM
Pharma
In Focus
Manufacturing

The obe­si­ty drug race is be­ing fought on the man­u­fac­tur­ing floor as GLP-1 ri­vals make plans to catch lead­ers

Anna Brown

News Reporter

Ever since the weight loss drug craze cre­at­ed near-un­prece­dent­ed de­mand, the first two com­pa­nies to mar­ket have been do­ing every­thing they can to meet it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

Pfiz­er shares new de­tails on obe­si­ty pipeline, hints at ‘oth­er op­por­tu­ni­ties’

GSK buys au­toim­mune T cell en­gager for $300M up­front from Chim­a­gen

No­var­tis takes $800M Mor­phoSys write­down mere months af­ter clos­ing ac­qui­si­tion

No­var­tis high­lights over­all M&A track record fol­low­ing Mor­phoSys im­pair­ment

Fol­low­ing March in­spec­tion, No­vo Nordisk's semaglu­tide man­u­fac­tur­ing fa­cil­i­ty cit­ed by FDA

A service from the Financial Times